Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
A cornerstone of preclinical development for evaluating compound targeting, accumulation, and clearance.
Comprehensive Radioligand Binding Assays for Precise and Reliable Drug Development Support.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Capture Body Composition Imaging Biomarkers with Confidence
The development of GLP-1 agonists and other therapies for weight loss and obesity is evolving and so is the advancement of imaging biomarkers for body composition profiling. The options to delineate and quantify muscle and lean mass are getting more sophisticated, so determining which imaging modality, anatomical coverage, and analysis methods to use can be critical to your obesity clinical trial outcomes.
Perceptive Imaging combines the right experience and the right people to help you navigate the nuances of imaging in weight loss clinical trials and to drive the success of your development program.
Image credit: AMRA Medical
Perceptive has provided imaging services to quantify lean and/or adipose tissue in nearly 80 clinical trials to date, contributing to 8 regulatory approvals.
You can rely on the scientific experts at Perceptive Imaging to identify the appropriate techniques to meet your weight loss clinical trial objectives. Their in-depth understanding of the different modalities involved in body composition imaging, including DXA, CT, and MRI and can help you reliably measure muscle and fat changes in the whole body or at specific anatomic locations.
Learn why you can rely on Perceptive Imaging for your obesity clinical trials.
Perceptive’s expertise spans the gamut of imaging that’s required to demonstrate safety and efficacy during obesity clinical trials, including:
Learn more about Perceptive’s expertise in weight loss clinical trial imaging
Dr. Warner has managed the imaging aspects of 100+ clinical trials in rheumatology (RA, PsA, SpA, AS and OA), orthopedics, and body composition, providing medical expertise in study design, protocol standardization, and customization of analysis software tools. She co-authored “The Official Positions of the International Society for Clinical Densitometry: Acquisition of Dual-Energy X-ray Absorptiometry Body Composition and Considerations Regarding Analysis and Repeatability of Measures”[2013]. Her scientific research has included a focus on the use of imaging to quantify the effects of interventions on muscle, bone and fat in various disease indications and metabolic disorders.
Dr. Syed has extensive experience in bone analysis techniques and imaging endpoints in bone, connective tissue, and body composition studies. He has 25 combined years of academic/ pharmaceutical industry experience, has led over 30 MSK imaging projects at Perceptive, and has 50+ publications and presentations in women’s bone health, aging, immunology, inflammation, endocrinology and cancer biology. He has expertise in osteoporosis, inflammation, and aging with animal models and human trials He has significant experience with in-vivo imaging modalities such as X-ray, MRI, DEXA, pQCT, and microCT; as well as bone and soft tissue histomorphometry in human/animal biopsies and tissues.
Independent clinical event adjudication of efficacy and safety endpoints in obesity trials is essential to fully understand the potential benefits and risks of GLP-1 agonists and other treatments beyond the loss of weight.
Perceptive’s Clinical Adjudication team has a combined 60 years of experience managing and supporting clinical event adjudication services, including extensive work in several obesity trials. Our robust, regulatory-compliant, efficient processes can help you mitigate the challenges associated with adjudicating efficacy and safety endpoints in obesity and weight loss trials.
Stay on top of industry trends and learn how Perceptive is helping sponsors and CROs design and implement obesity clinical trials effectively – and efficiently.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
